Lumida
/FATE
⌘K
Fate Therapeutics Inc

Fate Therapeutics Inc

FATE
$2.78USD+1.83%+0.05 today

MARKET CAP

324.0M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$1
$3

AI Summary

Stalk
Buy NowMedium

Stock is in a Stage 2 uptrend medium-term bullish environment, showing a pullback into rising EMAs that have held support, offering a timely buy opportunity despite a Bullish Exhaustion pattern that signals possible short-term fatigue.

  • FDA cleared FT839 IND, enabling late-2026 basket trial in multiple autoimmune diseases.
  • FT819 Phase I data: all four lupus patients hit rCRISS ≥25 with mRSS improvement.
  • Q2 ’23 net loss of $52.8M and Q1 ’24 revenue plunged to $1.9M.
Full analysis →
Insider Trades20 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
May 20, 2026SellFATECindy Tahl25,590$1.88$324.0M-13.93%+205.49%$48.1K-3.91%Buy Now
May 20, 2026SellFATEBahram ValamehrPresident and CEO28,946$1.88$324.0M-13.93%+205.49%$54.5K-4.35%Buy Now
May 6, 2026BuyFATECindy Tahl166,664$1.25$324.0M-13.93%+205.49%$208.0K+10.39%Buy Now
Jan 9, 2026SellFATEBahram ValamehrPresident and CEO5,190$1.07$324.0M-13.93%+205.49%$5.6K-1.55%Buy Now
Jan 9, 2026SellFATECindy Tahl10,589$1.06$324.0M-13.93%+205.49%$11.3K-2.66%Buy Now
Aug 4, 2025SellFATECindy Tahl9,037$1.06$324.0M-13.93%+205.49%$9.6K-2.22%Buy Now
Aug 4, 2025SellFATEBahram ValamehrPresident and CEO14,466$1.06$324.0M-13.93%+205.49%$15.4K-4.14%Buy Now
Jan 10, 2025SellFATECindy Tahl5,654$1.55$324.0M-13.93%+205.49%$8.8K-1.65%Buy Now
Jan 10, 2025SellFATEJerome Charles Bressi5,980$1.55$324.0M-13.93%+205.49%$9.3K-2.17%Buy Now
Jan 10, 2025SellFATEBahram ValamehrPresident and CEO8,705$1.54$324.0M-13.93%+205.49%$13.4K-2.43%Buy Now
Mar 4, 2024SellFATEEdward J Iii DulacChief Financial Officer2,447$7.77$324.0M-13.93%+205.49%$19.0K-2.35%10b5-1Buy Now
Jan 29, 2024SellFATEEdward J Iii DulacChief Financial Officer1,849$5.00$324.0M-13.93%+205.49%$9.2K-1.75%10b5-1Buy Now
Jan 9, 2024SellFATEEdward J Iii DulacChief Financial Officer7,028$4.37$324.0M-13.93%+205.49%$30.7K-6.23%Buy Now
Jan 9, 2024SellFATECindy TahlGeneral Counsel and Secretary10,874$4.37$324.0M-13.93%+205.49%$47.5K-7.10%Buy Now
Jan 9, 2024SellFATEBahram ValamehrChief R&D Officer11,271$4.38$324.0M-13.93%+205.49%$49.4K-6.66%Buy Now
Jan 9, 2024SellFATEJ Scott WolchkoPresident and CEO14,391$4.37$324.0M-13.93%+205.49%$62.9K-3.73%Buy Now
Jan 2, 2024SellFATEEdward J Iii DulacChief Financial Officer5,182$3.66$324.0M-13.93%+205.49%$19.0K-4.39%10b5-1Buy Now
Dec 18, 2023SellFATEEdward J Iii DulacChief Financial Officer1,585$3.50$324.0M-13.93%+205.49%$5.5K-1.33%10b5-1Buy Now
Nov 9, 2023SellFATECindy TahlGeneral Counsel and Secretary24,363$2.40$324.0M-13.93%+205.49%$58.5K-13.72%10b5-1Buy Now
Aug 18, 2023SellFATEEdward J Iii DulacChief Financial Officer4,718$2.80$324.0M-13.93%+205.49%$13.2K-3.80%Buy Now